Global Health
Our aim is to accelerate global innovation to prevent, manage and treat drug-resistant infections, especially in the most impacted communities.
Resistance to antibiotics, antivirals and antifungals is driving prolonged illness, escalating healthcare costs, and causing a rising number of deaths, especially in low-resource settings.
These drug-resistant infections threaten to erode decades of medical progress and are some of the biggest threats facing human health.
We are accelerating innovation by addressing gaps across therapeutics, diagnostics, and clinical practice, through our leadership, collaboration and influence.
Our approach
Through strategic partnerships, we aim to help accelerate sustainable global innovation in drug-resistant infections.
Partnerships and initiatives
Grand Challenges African Drug Discovery Accelerator programme
In collaboration with the Bill & Melinda Gates Foundation we are investing £6 million in the Grand Challenges African Drug Discovery Accelerator (GC ADDA) programme.
PACE
A £30 million initiative with Innovate UK and Medicines Discovery Catapult, driving new developments to tackle antimicrobial resistance.
iiCON and the Liverpool School of Tropical Medicine
We are partnering with the Liverpool School of Tropical Medicine (LSTM) to launch a new £2.7 million Translational Development Fund.
The Francis Crick Institute and the Crick Africa Network
We have partnered with the Crick Africa Network (CAN), to provide £7.5 million towards community science programmes.
Who to contact
-
Ghada Zoubiane
Read bio: Ghada Zoubiane
-
Magalie Rocheville
Read bio: Magalie Rocheville
-
Kelly Chibale
Read bio: Kelly Chibale
-
Julie Brady
Read bio: Julie Brady
Related stories
-
News releasesLifeArc and the Gates Foundation launches groundbreaking new projects to lower the cost of monoclonal antibody production
Read more: LifeArc and the Gates Foundation launches groundbreaking new projects to lower the cost of monoclonal antibody production -
BlogsWe must confront this silent pandemic as a global collective
Read more: We must confront this silent pandemic as a global collective -
News releasesPACE announces £6 million funding for antibacterial treatment innovations to fill critical gap in R&D pipeline
Read more: PACE announces £6 million funding for antibacterial treatment innovations to fill critical gap in R&D pipeline
See our other focus areas
Motor Neuron Disease & Rare Dementias
Our vision is a world where motor neuron disease is preventable and treatable.
Chronic & Rare Respiratory Disease
Our vision is improved quality of life for those living with cystic fibrosis and bronchiectasis.
Rare Disease
Our vision is an ecosystem working together to get discoveries and treatments to rare disease patients faster.
Childhood Cancer
Our vision is to drive life-changing innovations for children with cancer.
Contact us
In submitting your personal data via this form, you consent to being contacted via the details provided so that your enquiry can be responded to. If you would like your data to be removed, please email info@lifearc.org.
Please see our Privacy Policy in relation to the personal data you submit to us through this page.
This site is protected by reCAPTCHA and the Google privacy policy and terms apply.